Vaccine for use in the prophylaxis and/or treatment of a disease
AssigneeInprother Aps
InventorsPeter Holst, Christian Thirion, Lasse Neukirch
Life of this patent
Estimating the term…
Abstract
The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
Claims16
An endogenous retrovirus (ERV) envelope protein or an immunogenic part thereof, wherein the ERV envelope protein or the immunogenic part thereof comprises an immunosuppressive domain (ISD), wherein the ISD comprises a mutation that render(s) the ISD less active, wherein the ERV envelope protein (Env) or an immunogenic part thereof is linked to a Gag protein via a linker, and wherein the linker is p2A.
A method of treatment and/or prophylaxis of a cancer in a patient comprising administering to a patient, first, an adenoviral vector comprising a nucleic acid molecule encoding an endogenous retrovirus (ERV) envelope protein or an immunogenic part thereof and, second, said nucleic acid molecule, including a mutated immunosuppressive domain (ISD) that is less active.
Dependencies are inferred from the claim text.